- Home
- SDHC vs MDXG Comparison
SDHC vs MDXG Comparison
Compare SDHC & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHC
- MDXG
- Stock Information
- Founded
- SDHC 2008
- MDXG 2006
- Country
- SDHC United States
- MDXG United States
- Employees
- SDHC N/A
- MDXG N/A
- Industry
- SDHC
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- SDHC
- MDXG Health Care
- Exchange
- SDHC Nasdaq
- MDXG Nasdaq
- Market Cap
- SDHC 1.3B
- MDXG 1.1B
- IPO Year
- SDHC 2024
- MDXG N/A
- Fundamental
- Price
- SDHC $25.08
- MDXG $9.12
- Analyst Decision
- SDHC Hold
- MDXG Strong Buy
- Analyst Count
- SDHC 6
- MDXG 5
- Target Price
- SDHC $29.60
- MDXG $12.00
- AVG Volume (30 Days)
- SDHC 161.4K
- MDXG 674.7K
- Earning Date
- SDHC 01-28-2025
- MDXG 02-26-2025
- Dividend Yield
- SDHC N/A
- MDXG N/A
- EPS Growth
- SDHC N/A
- MDXG N/A
- EPS
- SDHC 4.71
- MDXG 0.52
- Revenue
- SDHC $905,304,000.00
- MDXG $342,804,000.00
- Revenue This Year
- SDHC $27.04
- MDXG $9.56
- Revenue Next Year
- SDHC $14.47
- MDXG $9.19
- P/E Ratio
- SDHC $5.33
- MDXG $18.12
- Revenue Growth
- SDHC 17.46
- MDXG 10.93
- 52 Week Low
- SDHC $20.55
- MDXG $5.47
- 52 Week High
- SDHC $39.50
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- SDHC 38.98
- MDXG 53.35
- Support Level
- SDHC $21.99
- MDXG $8.50
- Resistance Level
- SDHC $25.31
- MDXG $9.71
- Average True Range (ATR)
- SDHC 0.98
- MDXG 0.30
- MACD
- SDHC 0.24
- MDXG -0.04
- Stochastic Oscillator
- SDHC 54.88
- MDXG 51.24
About SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. The company has organized into five geographical segments so their reportable segments include Atlanta, Raleigh, Charlotte, Nashville, and Alabama which consists of both Birmingham and Huntsville.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.